Luminex Corporation and ViroNovative Announce License Agreement for Human Metapneumovirus Rights

16-Jul-2008

Luminex Corporation and ViroNovative BV announced that the companies have signed a licensing agreement that gives Luminex worldwide rights to use ViroNovative's human metapneumovirus (hMPV) intellectual property in the xTAG Respiratory Viral Panel (RVP). Under the terms of the agreement, rights to ViroNovative's hMPV intellectual property will be extended to Luminex's distributors and end-user customers around the world.

"We are pleased to announce this license agreement in place with ViroNovative for human metapneumovirus," said Jeremy Bridge-Cook, vice president of Luminex Molecular Diagnostics. "This virus is of increasing concern to healthcare providers worldwide. Having this license as part of our xTAG RVP assay is important to us as it allows our customers to use this cutting-edge test without the need to individually secure rights to this intellectual property."

Luminex's xTAG RVP received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on January 3, 2008. The test was cleared for the detection and identification of 12 viruses and viral subtypes that are together responsible for more than 85 percent of respiratory viral infections. xTAG RVP is the first multiplexed nucleic acid test for respiratory viruses cleared for in vitro diagnostic use by the FDA and is the first and only test cleared by FDA for the detection of hMPV.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures